Aims Cardiac resynchronization therapy (CRT) with or without a defibrillator reduces
morbidity and mortality in selected patients with heart failure (HF) but response can be …

Heart failure (HF) and atrial fibrillation (AF) are two conditions that are likely to dominate the
next 50 years of cardiovascular (CV) care. Both are increasingly prevalent and associated …

Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in
2006, much has changed in the care for patients with HF. Over the past decade, the HF …

Aims The benefit of prophylactic implantable cardioverter-defibrillator (ICD) is not uniform
due to differences in the risk of life-threatening ventricular tachycardia (VT)/ventricular …

Background: Comprehensive studies have confirmed that particulate matter air pollution
could trigger myocardial infarction, heart failure and reduce heart rate variability; however …

Background Cardiac resynchronisation therapy (CRT) reduces morbidity and mortality in
appropriately selected patients with heart failure and is strongly recommended for such …

Objective Implantable cardioverter defibrillators (ICD), cardiac resynchronisation therapy
pacemakers (CRT-P) and the combination therapy (CRT-D) have been shown to reduce all …

Aims In atrial fibrillation (AF), mortality remains high despite effective anticoagulation. A
model predicting the risk of death in these patients is currently not available. We developed …

Although tremendous progress has been made in conventional treatment for ischemic heart
disease, it still remains a major cause of death and disability. Cell-based therapeutics holds …

The capacity of stem and progenitor cells to stimulate cardiac regeneration has been studied
for almost 20 years, with very promising preclinical data and mixed clinical results. Several …